Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics Sets-up Laboratory at Stevenage Bioscience Catalyst
Laboratory facilities initiated to optimise development of product pipeline for the prevention of cancer therapy induced side-effects
NG11-2 Phase-Ib Dose Escalation Phase Completes & Dose Expansion Cohort Open to Enrolment
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
VasoDynamics initiates NG13 optimisation development with key appointment
Preclinical team strengthened to optimise development of NG13 for the prevention of chemotherapy-induced alopecia
Labour Shadow Health Team Visit Stevenage Bioscience Catalyst and Discuss VasoDynamics’ Technology
New treatments for the prevention of the side-effects from anti-cancer therapy
NG11-2 Phase-Ib Dose Escalation Clinical Study Progresses to Final Dose Level
A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer
VasoDynamics files global patent (PCT) for the methods to select patients for the clinical studies on radiation-induced oral mucositis
Platform products Intellectual Property protection extended to 2043